2023 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上 市规则（2020 年 12 月修订）》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关法律、法规的规定，西部证券股份有限公司 （以下简称"保荐人、"西部证券"）作为爱威科技股份有限公司（以下简称 "爱威科技"、"公司"）持续督导工作的保荐人，负责爱威科技上市后的持 续督导工作，并出具本持续督导半年度跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并针对 | 保荐人己建立健全并有效执行 了持续督导制度，并制定了相 | | 1 | | | | | 具体的持续督导工作制定相应的工作计划 | 应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始 | 保荐人己与爱威科技签订《保 | | | 前，与上市公司或相关当事人签署持续督导协 | 荐协议》，该协议明确了双方 | | | 议，明确双方在持续督导期间的权利义务，并报 | 在持续督导期间的权利和义 | | | 上海证券交易所备案 | ...

重要内容提示： 证券代码：688067 证券简称：爱威科技 公告编号： 2023-028 爱威科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 投资者可于 2023 年09 月 06 日(星期三) 至09 月 12 日(星期二)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 aveir@c- ave.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 爱威科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 30 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营 成果、财务状况，公司计划于 2023 年 09 月 13 日下午 13:00-14:00 举行 2023 年半 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度经营成果及 财务指标的具体情况与投资者进行互动交 ...

证券代码：688067 证券简称：爱威科技 公告编号：2023-023 爱威科技股份有限公司 第四届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会召开情况 爱威科技股份有限公司（以下简称"公司"）于 2023 年 8 月 29 日召开第四 届监事会第十二次会议，本次会议应出席监事 3 人，实际出席监事 3 人。会议 由监事会主席王晓东先生主持，以现场方式召开。本次会议的通知、召开及审 议程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 1 议案内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《爱威科技股份有限公司关于 2023 年半年度募集资金存放与实际使用情况的 专项报告》。 监事会认为：公司 2023 年半年度募集资金存放和实际使用情况符合《上 海证券交易所科创板股票上市规则（2020 年 12 月修订）》、《上海证券交易所科 创板上市公司自律监管规则适用指引第 1 号——规范运作》、公司《募集资金管 理制度》等相关法律、法规和制度文件的 ...

爱威科技股份有限公司独立董事关于 公司第四届董事会第十二次会议相关事项的 独立意见 根据《中华人民共和国公司法》、《关于在上市公司建立独立董事制度的指导 意见》等法律、法规、规范性文件及《公司章程》《公司独立董事工作制度》等 相关规定，作为爱威科技股份有限公司（以下简称"公司"）的独立董事，在认 真阅读有关文件资料后，基于独立、客观判断的原则，对公司第四届董事会第十 二次会议审议的相关事项，发表如下独立意见： 一、关于公司《关于 2023 年半年度募集资金存放与实际使用情况的专项报 告》的独立意见 报告期内，公司对募集资金进行了专户存储和专项使用，募集资金的存放与 使用情况与公司信息披露一致，符合《上市公司监管指引第 2 号—上市公司募集 资金管理和使用的监管要求》、《上海证券交易所上市公司募集资金管理办法 （2013 年修订）》等法律法规和公司募集资金管理制度的规定，不存在违规存放 和使用募集资金的情形，亦不存在改变或变相改变募集资金用途及损害股东利益 的情况，同意公司《关于 2023 年半年度募集资金存放与实际使用情况的专项报 告》。 二、关于《调整公司使用暂时闲置自有资金进行现金管理方案的议案》的 独立 ...

爱威科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年年度报告及 2023 年第一季度报告，为便于广大投资者更全面深入地了解公 司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 06 月 12 日下午 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心 的问题进行交流。 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 06 月 12 日(星期一) 下午 15:00 - 16:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.ssein fo.com） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 06 月 05 日(星期一)至 06 月 09 日(星期五)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮 ...

2023 年第一季度报告 证券代码：688067 证券简称：爱威科技 爱威科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 同期增减变动幅 | | --- | --- | --- | | | | 度(%) | | 营业收入 | 40,898,718.07 | -11.24 | | 归属于上市公司股东的净利润 | 2,145,251.44 | -63.26 | | 归属于上市公司股东的扣除非经常 | -1,568,972.31 | -138.65 | | 性损益 ...

Financial Performance - The company's operating revenue for 2022 was ¥196,774,016.32, a decrease of 6.60% compared to ¥210,668,650.51 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥17,973,042.73, down 42.53% from ¥31,275,040.94 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,272,486.25, a decline of 73.85% from ¥23,985,348.09 in 2021[21]. - The cash flow from operating activities for 2022 was ¥29,739,892.63, a decrease of 36.97% compared to ¥47,185,681.68 in 2021[21]. - The gross profit margin for the main business decreased by 5.32 percentage points to 53.49%[90]. - The company's R&D expenses increased by 6.01% to CNY 33,078,377.41, reflecting a commitment to ongoing research and development[88]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth[187]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter, indicating improved financial health[135]. Dividend Distribution - The proposed cash dividend distribution is RMB 1.00 per 10 shares, totaling RMB 6,800,000.00, which accounts for 37.83% of the net profit attributable to ordinary shareholders for 2022[5]. - The profit distribution plan is subject to approval at the 2022 annual general meeting[5]. - The company emphasizes a stable profit distribution policy, balancing operational conditions and sustainable development[155]. Corporate Governance - The company does not have any special arrangements for corporate governance[8]. - The company has established a scientific and standardized corporate governance structure, complying with relevant laws and regulations[126]. - The company did not experience any major violations or defects in its governance practices during the reporting period[126]. - The company’s governance practices align with the requirements set by the China Securities Regulatory Commission[126]. - The company has established measures to stabilize its stock price if the closing price falls below the latest audited net asset per share for 20 consecutive trading days[197]. Research and Development - The company aims to enhance its research and development capabilities in molecular diagnostics and immunodiagnostics to improve diagnostic accuracy and efficiency[14]. - The total R&D investment for the year reached 34.98 million, a 12.09% increase compared to the previous year, with R&D expenses accounting for 17.77% of total revenue[63]. - The company is committed to continuous research and development to maintain its technological leadership in the medical testing field[53]. - The company is focused on original innovation and technology integration to meet market demands and enhance its competitive edge[53]. Market Expansion - The company is exploring potential market expansion opportunities both domestically and internationally to increase its market share[14]. - The company plans to enhance its product offerings in the primary healthcare market, focusing on AI-assisted diagnostic products[116]. - The company aims to expand its sales channels, including online and offline strategies, to increase market share[117]. - The company is actively expanding its product lines and enhancing its technological capabilities to maintain its competitive edge in the market[75]. Product Development - The company completed multiple new product developments, including automated inspection products covering various clinical specimen testing fields[33]. - The company has developed a urine analysis technology that automates the review of abnormal indicators, improving analysis accuracy and reducing the workload of operators[55]. - The company has introduced multiple home-use POCT products, including urine and fecal tests, with some achieving small-scale sales, targeting the grassroots and civilian medical markets as key growth areas[118]. - The company is developing multi-functional testing instruments capable of analyzing various samples, with a total investment of 940 million and 39.24 million invested in the current period[68]. Risk Management - The company has detailed the major risks and countermeasures in the report, which can be found in the section on risk factors[4]. - The company faces risks related to new product development, including long development cycles and regulatory approval processes that can take several years[82]. - The company is exposed to potential price declines due to rapid technological advancements and government price controls in the medical testing sector[83]. Intellectual Property - A total of 228 patents were obtained, including 77 domestic invention patents and 13 foreign invention patents, indicating strong intellectual property protection[34]. - The company has implemented multiple measures to protect intellectual property rights and has established an information security management system to safeguard its information[183]. Customer Relations - The company has established a strong brand reputation and customer loyalty through its commitment to product quality and after-sales service[79]. - Customer satisfaction ratings have improved to 90%, reflecting the success of recent service enhancements[135]. Financial Management - The company has established a detailed management system for the use of raised funds to ensure compliance and protect investor interests[200]. - The company will manage raised funds in a dedicated account to ensure they are used legally and appropriately[200]. - The company has implemented cost-cutting measures aimed at reducing operational expenses by 5% in the upcoming year[187].

证券代码：688067 证券简称：爱威科技 编号：2022-001 爱威科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者 \n关系活 \n动类别 | 特定对象调研 \n媒体采访 \n新闻发布会 \n现场参观 | 分析师会议 \n业绩说明会 \n路演活动 \n其他（电话会议） | | 时间 | 2022 年5月 10日 | 11:00-12:00 | | | 地点 上证路演中心网络互动 | | | | 董事长兼总经理：丁建文 | | | 公司接 待人员 姓名 | ...

证券代码：688067 证券简称：爱威科技 公告编号：2022-032 爱威科技股份有限公司 关于参加湖南辖区上市公司 2022 年 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，爱威科技股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合主 办的"湖南辖区上市公司 2022 年投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采用网络远程的方式举行。投资者可以登录"全景路演"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动。活动时间 为 2022 年 9 月 29 日（星期四）下午 15：30-16：55。 届时，公司董事会秘书及证券事务代表将通过网络文字形式与投资者进行 交流与沟通，欢迎广大投资者积极参与。 特此公告。 爱威科技股份 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[1] - The company's revenue for the first half of 2022 was approximately ¥93.48 million, a decrease of 3.93% compared to ¥97.31 million in the same period last year[22] - The net profit attributable to shareholders for the first half of 2022 was approximately ¥11.95 million, down 5.30% from ¥12.62 million in the previous year[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥6.60 million, a significant decrease of 39.56% compared to ¥10.92 million in the same period last year[22] - The basic earnings per share for the first half of 2022 was ¥0.18, a decline of 28.00% from ¥0.25 in the previous year[20] - The diluted earnings per share also stood at ¥0.18, reflecting the same 28.00% decrease compared to the previous year[20] - The gross profit margin for the first half of 2022 was reported at 45%, an improvement from 40% in the same period last year[1] - The overall gross profit margin decreased from 58.91% in the previous year to 53.50% in the current reporting period[21] - The net cash flow from operating activities for the first half of 2022 was approximately ¥2.97 million, an increase of 5.77% from ¥2.81 million in the same period last year[22] Research and Development - The company has invested RMB 20 million in R&D for new technologies, focusing on machine vision and digital imaging[1] - The company's R&D expenditure accounted for 18.29% of operating revenue, an increase of 6.58 percentage points from 11.71% in the previous year[20] - Total R&D investment reached CNY 1,709.94 million, a significant increase of 50.12% compared to the same period last year[46] - The company employs a research and development strategy that emphasizes original innovation, aiming to continuously develop new products and technologies based on market demand[34] - The company has a total of 215 authorized patents, including 74 domestic invention patents and 12 overseas patents, as well as 23 software copyrights[42] - The company has completed the design and development of a COVID-19 antigen test kit, with clinical trial service fees capitalized at CNY 2,863,600.85[48] - The company has developed a range of automated medical inspection instruments, including urine, feces, and blood analysis devices, significantly improving inspection speed and accuracy[33] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1] - The company is exploring potential acquisitions to strengthen its product portfolio and increase market competitiveness, with a budget of 500 million allocated for this purpose[110] - Strategic partnerships are being formed to enhance distribution channels, aiming to increase sales by 15% in the upcoming quarters[110] - The company is focused on the integration of artificial intelligence with medical testing, moving towards full laboratory automation and standardization[27] - The company is expanding its product offerings into the consumer medical testing market, launching various home-use POCT products, with some already achieving small-scale sales on e-commerce platforms[34] Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which are detailed in the risk factors section[1] - The company faced risks related to new product development, including potential delays in obtaining regulatory approvals, which could adversely affect market promotion[68] - The company is exposed to industry competition risks, with increasing competition from both domestic and international firms in the in vitro diagnostics market[71] - The company is at risk of losing key technical personnel, which could negatively impact new product development and core technology security[69] Compliance and Governance - No non-operational fund occupation by controlling shareholders was reported during the period[1] - The company strictly adheres to national environmental protection laws and regulations, ensuring compliance during production operations[88] - The company has signed contracts with third-party environmental agencies for the safe disposal of pollutants generated during production[88] - The company has committed to maintaining stock lock-up for 36 months post-IPO, ensuring stability in shareholding[91] - The company will ensure timely and accurate disclosure of information regarding any share reductions[95] Future Outlook - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% year-on-year[1] - Future outlook includes continued investment in R&D to drive technological advancements and improve product offerings[39] - The company plans to strengthen internal controls and operational efficiency to mitigate risks and enhance decision-making processes[104] - The company is considering strategic acquisitions to bolster its market presence and diversify its product offerings[167]